跳至主要内容
临床试验/NCT02042287
NCT02042287已完成4 期

Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV)

Insel Gruppe AG, University Hospital Bern1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2014年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
32
试验地点
1
主要终点
Proportion (percentage) of patients with treatment success based on the Amsel criteria at week 3.

研究概览

简要总结

Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age. Women with symptomatic BV may present with malodorous discharge that is off-white, thin, and homogenous and has a fishy smell especially after intercourse. It is of importance to treat women with BV, as this condition is associated with serious risks, such as an increased risk of preterm birth in pregnant women, and particular vulnerability to the acquisition of sexually transmitted disease (STD). The pathophysiology of BV consists of changes in the microbiologic composition of the vaginal flora. The treatment of choice for BV is oral metronidazole for 7 days. Although the available antibiotic therapies produce good results in the short term, symptomatic BV persists or recurs at 3 months in up to 50% to 70% of patients, with long-term recurrence approaching 85%. An alternative treatment option may be a vaginal acid gel which aims to optimize the vaginal milieu. The aim of this pilot study is to assess the efficacy of Gynofit® vaginal gel (lactic acid and glycogen) compared to oral metronidazole in the treatment of BV.

详细描述

Background

Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age, with an estimated prevalence of 29% in the general population of women aged 14 to 49 years.

Women with symptomatic BV may present with malodorous discharge that is off-white, thin, and homogenous and has a fishy smell especially after intercourse. However, only the minority of women with BV is symptomatic.

Regardless of the symptoms, it may be of importance to treat women with BV, as this condition is associated with serious risks, such as an increased risk of preterm birth in pregnant women, particular vulnerability to the acquisition of sexually transmitted disease (STD), including gonorrhea, chlamydia trachomatis, genital herpes and HIV and a possibly higher risk of pelvic inflammatory disease (PID). Moreover, endometrial bacterial colonization, plasma-cell endometritis, postpartum fever, post-hysterectomy vaginal cluff cellulitis and post-abortal infection seem to be associated with BV.

The pathophysiology of BV consists of changes in the microbiologic composition of the vaginal flora. In the healthy vaginal flora, lactobacilli are the predominant bacteria, producing lactic acid and H2O2, maintaining a pH<4.5 and inhibiting the growth of other organisms. In BV, the concentration of H2O2-producing lactobacilli is reduced and other species become more prevalent, notably Gardnerella vaginalis, Prevotella species, Porphyromonas species, Bacteroides species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and Mobiluncus species. These vaginal anaerobes produce carboxylase enzymes, breaking down peptides to amines, which get volatile and malodorous with the increased pH. More over the amines increase vaginal transudation and squamous epithelial cell exfoliation, leading to the typical discharge in BV. With the increased pH, Gardnerella vaginalis can adhere to squamous epithelial cells and create a biofilm. The mechanism by which this floral imbalance occurs is not clear, but sexual activity seems to be a major risk factor, as BV does not occur in sexual inactive women. Additionally, multiple or new sexual partners, frequency of vaginal intercourse, vaginal douching, and cigarette smoking have also been identified as risk factors, whereas the use of condoms had a protective effect.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • > 18 years old
  • Acute symptomatic BV
  • Signed informed consent
  • Exclusion Criteria
  • Insufficient knowledge of German
  • Illiteracy
  • Pregnancy
  • Acute illness
  • Known allergies against ingredients of the investigational products

排除标准

  • 未提供

研究组 & 干预措施

1: Gynofit®

Experimental

Vaginal lactic acid gel

干预措施: Vaginal lactic acid and glycogen gel (Device)

2: metronidazole

Active Comparator

Oral antibiotic

干预措施: Metronidazole (Drug)

结局指标

主要结局

Proportion (percentage) of patients with treatment success based on the Amsel criteria at week 3.

时间窗: Visit 1 (day 0) and Visit 2 (day 21)

This is a binary parameter indicating remission from BV.

次要结局

  • Mean symptom score-changes (as pre-post-difference) regarding severity of BV at week 3(Visit 1 (day 0) and Visit 2 (day 21))
  • Percentage of patients with a complete relief from symptoms(Visit 1 (day 0), Visit 2 (day 21), Visit 3 (day 84) and Visit 4 (day 252)
  • Proportion (percentage) of patients with treatment success based on the Nugent score at week 3.(Visit 1 (day 0) and Visit 2 (day 21))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验